Retina

In this study, the investigators retrospectively reviewed all study patients who underwent pars plana vitrectomy with silicone oil tamponade for postsurgical endophthalmitis.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

The US and German collaborative study found performing vitrectomy with silicone oil tamponade to manage postoperative endophthalmitis led to a significant improvement in visual acuity (VA) and had a low complication rate.

Faricimab could lower treatment burden for patients compared to aflibercept

J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team about clinical characteristics of macular holes that close without surgery at the 2023 ASRS annual meeting.

The partnership will drive Kiora's development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration.

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team to share information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

The Modern Retina team caught up with one of our board members, Fernando Arevalo, MD, PhD, FACS, FASRS, who shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated with retinoschisis cases at the 2023 ASRS annual meeting.

Matthew R. Starr, MD, discusses how secondary lens techniques have changed over time.

At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.

According to the company, a pair of presentations at the American Society of Retina Specialists annual meeting in Seattle highlight CLS-AX as a promising wet AMD treatment with a new mechanism of action and the potential for longer duration of effect than current therapies.

Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

The company noted at the American Society of Retina Specialists meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.